This press release contains forward-looking statements.

These statements are only of the date of this press release, and Genzyme undertakes no obligation to update or revise the statements.. This press release contains forward-looking statements, including statements relating to time limits for obtaining and present clinical trial data, the expected efficacy of alemtuzumab in MS and the comparison to current market products, the possibility of approval of alemtuzumab in MS and the continuation recruitment of patients in related MS clinical trials.

Campath has contains a warning that the information on cytopenias, infusion reactions, and infections. The most frequently reported side effects in patients with B-CLL were infusion reactions , cytopenias , infections other infections. In clinical trials, the frequency of infusion reactions highest in the first week of treatment. Other commonly reported side effects include vomiting, abdominal pain, insomnia and anxiety. The most commonly reported serious adverse reactions are cytopenias, infusion reactions, and immunosuppression / infections.

Genzyme and Bayer Schering Pharma AG, Germany are jointly developing alemtuzumab in oncology, multiple sclerosis and other indications.The Terry presentations were by the gift by a gift from Bridgeport business man Dwight Harrington Terry. The lectureship brings scientist which religion, science and philosophy at the campus to avoid problems in relation to the opportunities to learn in which science and philosophy of consider religion, and the use of of religious for human well.

Proceedings of the Terry Lectures will be with an introduction from Yale University Press, with an introduction by a science journalist Carl Zimmer.

Friday, are loudspeaker contemporary American philosopher Alvin Plantinga of Notre Dame University;. A biologist Kenneth R. Brown University, and history of science Ronald Numbers, University of Wisconsin.